Psychiatric Times

Premier online and print content, written by and for #mentalhealth care physicians and professionals. Questions? Email: [email protected].

[Psychiatric Times @PsychTimes]

Is your adult ADHD patient covered from morning to night? Our expert panel talks treatment selection, all-day symptom control, adherence, and when to add a non-stimulant. https://t.co/Ude6Atit2R #ADHD #Psychiatry

[Psychiatric Times @PsychTimes]

In this week's episode of "Psyched Perspectives," host @tapkidmd and guest Diego Regalado, MD, discuss immigrant mental health and the importance of cultural humility. https://t.co/LVQsh0H3jF

[Psychiatric Times @PsychTimes]

🧠 Today is #InternationalStutteringAwarenessDay.

This year, we shared the first ever interdisciplinary consensus guidelines on stuttering.

🔗 Read them here: https://t.co/NbbKK7gtsM

[Psychiatric Times @PsychTimes]

🎃 The entire October issue of Psychiatric Times is now live on our website. Read it here: https://t.co/tsCdjxBcS4

[Psychiatric Times @PsychTimes]

In our latest CME article, learn how to recognize historical and persistent barriers to the ethical use of long-acting injectable antipsychotics. https://t.co/6v9BSEVW1U

[Psychiatric Times @PsychTimes]

Adult ADHD is more common than many clinicians think, and symptoms often look nothing like the childhood picture. Drs. Lentzsch-Parcells, Patel, and Feld break down diagnosis, comorbidities, and burden in our new Peer Exchange. https://t.co/NxqGd1hLFC #ADHD

[Psychiatric Times @PsychTimes]

According to a new review, ADHD medications may help improve brain fog in perimenopausal women. https://t.co/Nrx0mwwzwv

[Psychiatric Times @PsychTimes]

🎙️ Episode 2 of The Psych Consult: Second Opinion is here!

Claire Brandon, MD, and endocrinologist Caroline Messer, MD, discuss where thyroid disease and psychiatric illness overlap.

🔗 https://t.co/KVJNdtN4Sl

[Psychiatric Times @PsychTimes]

🦠 Phase 2 signal-finding trial of bezisterim for the treatment of long COVID shows safety and symptom gains, with strongest benefits for severe fatigue, post-exertional malaise, and cognitive issues. https://t.co/vg5nIDaPIu

[Psychiatric Times @PsychTimes]

How is schizophrenia management evolving? Attend our live national broadcast to explore real-world strategies to manage side effects, support treatment persistence, and optimize long-term functional outcomes in schizophrenia. Register Today! https://t.co/omw6He3wRc

[Psychiatric Times @PsychTimes]

🏃 Athletes can feel the relief a substance gives them long before they can see what it costs.

Check out this composite case of cannabis use in a track athlete to learn more about how to assess. https://t.co/njCyatUiAs

[Psychiatric Times @PsychTimes]

A psychiatric nurse practitioner shares mentorship lessons, training fixes, and practical tips to close prescriber gaps and improve team-based care in this week's episode of "Psyched Perspectives."
https://t.co/3XB9jekf74

[Psychiatric Times @PsychTimes]

Today marks the first-ever Treatment-Resistant Depression Awareness Day in the US. https://t.co/Jwg45ibpnP

[Psychiatric Times @PsychTimes]

Routine symptom measures can sharpen psychiatric diagnosis.

Learn how to gather consistent, evidence-based measurements from the initial evaluation and throughout patient treatment from John Rush, MD, in our October cover: https://t.co/vbR3jb5t0B

[Psychiatric Times @PsychTimes]

Mental health care changes lives—and so do the clinicians behind it. 💚🌍

On #WorldMentalHealthDay, we’re reminded that progress in psychiatry means progress for every patient, family, and community. #MentalHealthAwareness #MentalHealth

[Psychiatric Times @PsychTimes]

🚨 The FDA has approved olanzapine (Weltruza) extended-release injectable suspension, a once-monthly subcutaneous long-acting injectable, for adults with schizophrenia. https://t.co/msiSo8994U

[Psychiatric Times @PsychTimes]

Check out the latest episode of "Psychopharm Today"! This month, host Jessica Gannon, MD, interviews Andrew A. Nierenberg, MD, about how a learning health network can transform bipolar disorder care.

Watch it here: https://t.co/QedaL5fily

Listen here: https://t.co/xqkufG0lo1

[Psychiatric Times @PsychTimes]

The October issue of Psychiatric Times is now live! This month, we're rethinking treatment resistance and measurement-based care.

Download the issue now and follow along as articles are shared throughout the month. https://t.co/ghCkRDRjhD

[Psychiatric Times @PsychTimes]

The FDA has cleared Motivista, a prescription digital therapeutic indicated for the negative symptoms of schizophrenia, as an adjunct to outpatient care. This is the first authorized treatment for negative symptoms of schizophrenia in the United States. https://t.co/JqKYf8JfD2

[Psychiatric Times @PsychTimes]

A recent study found that vortioxetine was consistently associated with improvements in depressive symptoms, though improvements in cognitive symptoms were inconsistent, with neutral-to-positive, predominantly domain-specific effects. https://t.co/Q0xIF1BuM4